Avanos Medical/$AVNS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Avanos Medical
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.
Ticker
$AVNS
Sector
Primary listing
NYSE
Employees
2,227
Headquarters
Website
Avanos Medical Metrics
BasicAdvanced
$497M
-
-$10.06
1.12
-
Price and volume
Market cap
$497M
Beta
1.12
52-week high
$23.14
52-week low
$9.30
Average daily volume
604K
Financial strength
Current ratio
2.645
Quick ratio
1.49
Long term debt to equity
15.136
Total debt to equity
17.686
Interest coverage (TTM)
3.50%
Profitability
EBITDA (TTM)
88.3
Gross margin (TTM)
53.24%
Net profit margin (TTM)
-66.89%
Operating margin (TTM)
6.63%
Effective tax rate (TTM)
3.33%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
1.64%
Return on equity (TTM)
-46.17%
Valuation
Price to revenue (TTM)
0.712
Price to book
0.64
Price to tangible book (TTM)
1.71
Price to free cash flow (TTM)
5.606
Free cash flow yield (TTM)
17.84%
Free cash flow per share (TTM)
1.909
Growth
Revenue change (TTM)
1.48%
Earnings per share change (TTM)
-6,168.30%
3-year revenue growth (CAGR)
-0.72%
10-year revenue growth (CAGR)
-8.21%
3-year earnings per share growth (CAGR)
325.45%
10-year earnings per share growth (CAGR)
37.29%
What the Analysts think about Avanos Medical
Analyst ratings (Buy, Hold, Sell) for Avanos Medical stock.
Bulls say / Bears say
Avanos posted Q2 2025 net sales of $175.0 million, a 1.9% increase year over year driven by strong demand in its Specialty Nutrition Systems and Pain Management & Recovery segments. (PR Newswire)
In Q2 2025, the Specialty Nutrition Systems segment delivered net sales of $102.7 million, up 5.1% year over year with 4.4% volume growth, underscoring above-market performance. (PR Newswire)
On September 15, 2025, Avanos acquired Nexus Medical, incorporating its TKO anti-reflux needleless connector technology into the Specialty Nutrition Systems portfolio, expected to be immediately accretive to revenue and EPS. (PR Newswire)
Avanos reported an operating loss of $74.5 million in Q2 2025, reflecting a $77.0 million non-cash goodwill impairment in its PM&R segment that weighed on profitability. (PR Newswire)
Adjusted EBITDA for Q2 2025 declined to $17.0 million from $26.8 million in the prior-year period, highlighting margin pressure and lower profitability. (PR Newswire)
Free cash flow in Q2 2025 was negative $4.2 million, compared to a $21.9 million inflow a year earlier, signaling potential cash generation challenges. (PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Avanos Medical Financial Performance
Revenues and expenses
Avanos Medical Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Avanos Medical stock?
Avanos Medical (AVNS) has a market cap of $497M as of October 14, 2025.
What is the P/E ratio for Avanos Medical stock?
The price to earnings (P/E) ratio for Avanos Medical (AVNS) stock is 0 as of October 14, 2025.
Does Avanos Medical stock pay dividends?
No, Avanos Medical (AVNS) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Avanos Medical dividend payment date?
Avanos Medical (AVNS) stock does not pay dividends to its shareholders.
What is the beta indicator for Avanos Medical?
Avanos Medical (AVNS) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.